Explorers on the frontier of
life-changing science.
At NGM, we are charting new paths and pushing beyond boundaries to discover and deliver medicines for people whose health and lives have been disrupted by disease.
NGM Bio has initiated its EMERALD Phase 2 Clinical Trial of NGM120 in Hyperemesis Gravidarum, also known as extreme pregnancy sickness.
Learn More About NGM120 and Hyperemesis Gravidarum
Our Pipeline
We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing significant unmet medical needs in diseases that impact the lives of millions around the world. We are exploring partnering opportunities across our full product candidate and research portfolio.
News Section